Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
Shengxiang Ren(Tongji University), Caicun Zhou(Tongji University), Jianjun Zou(Jiangsu Hengrui Medicine (China)), Yiping Zhang(National Health and Family Planning Commission), Hui Luo(Jiangxi Provincial Cancer Hospital), Yunchao Huang(Kunming Medical University), Shundong Cang(Henan University), Junyan Yu(Changzhi Medical College), Ying Cheng(Jilin Province Tumor Hospital), Renhua Guo(Sun Yat-sen University), Dongqing Lv(Wenzhou Medical University), Zeyu Yang(Jiangsu Hengrui Medicine (China)), Wei Shi(Jiangsu Hengrui Medicine (China)), Sheng Hu(Hubei Cancer Hospital), Jian Fang(Peking University), Wei Zhang(Nanchang University), Jianhua Chen(Hunan Cancer Hospital), Qiming Wang(Hunan Cancer Hospital), Rui Wang(Sun Yat-sen University), Yanjun Zhang(Shanxi Medical University), Donglin Wang(Shandong University), Xingxiang Xu(Northern Jiangsu People's Hospital), Tao Jiang(Tongji University), Jianhua Shi(Linyi People's Hospital), Zhiwu Wang(Tangshan People's Hospital), Yong Fang(Tongji Hospital), Xingya Li(Zhengzhou University), Gongyan Chen(Harbin Medical University), Chunyan Xing(Jinan Central Hospital), Wenxiu Yao(Sichuan Cancer Hospital), Yueyin Pan(University of Science and Technology of China), Yi Geng(Baoji City Central Hospital), Peiguo Cao(Central South University)
Cited by 311
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k